archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • NCPE Prasugrel (Efient®) Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Research ICORN Education Prasugrel Efient In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic Evaluation of Prasugrel Efient for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention Pharmacoeconomic Evaluation Commenced Completed Outcome July 2009 February 2010 Reimbursement Recommended The review group consider that prasugrel co administered with aspirin is cost effective in patients

    Original URL path: http://www.ncpe.ie/drugs/prasugrel-efient/ (2015-10-30)
    Open archived version from archive


  • NCPE Indacaterol (Onbrez®) Assessment | National Centre for Pharmacoeconomics
    Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Indacaterol Onbrez In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Review of Indacaterol Onbrez for the treatment of COPD Rapid Review Commenced Completed Outcome 15 01 2010 Full Pharmacoeconomic Evaluation not Recommended It is recommended that Indacaterol Onbrez should not be subjected to a

    Original URL path: http://www.ncpe.ie/drugs/indacaterol-onbrez/ (2015-10-30)
    Open archived version from archive

  • NCPE Dronedarone (Multaq®) Assessment | National Centre for Pharmacoeconomics
    Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Dronedarone Multaq In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Rapid Review Commenced Completed Outcome January 2010 12

    Original URL path: http://www.ncpe.ie/drugs/dronedarone-multaq/ (2015-10-30)
    Open archived version from archive

  • NCPE Ranolazine (Ranexa®) Assessment | National Centre for Pharmacoeconomics
    Submission Process HTA Guidelines Process Flowchart Submission Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Ranolazine Ranexa In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of Ranolazine Ranexa Rapid Review Commenced Completed Outcome 19 11 2009 Full Pharmacoeconomic Evaluation not Recommended Terms Conditions Sitemap National Centre for

    Original URL path: http://www.ncpe.ie/drugs/ranolazine-ranexa/ (2015-10-30)
    Open archived version from archive

  • NCPE Eslicarbazepine (Zebinix®) Assessment | National Centre for Pharmacoeconomics
    Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Eslicarbazepine Zebinix In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Eslicarbazepine Zebinix for the treatment of Epilepsy Rapid Review Commenced Completed Outcome August 2009 01 09 2009 Full Pharmacoeconomic Evaluation Recommended Company did not submit Eslicarbazepine Zebinix was reimbursed under the Community Drugs Schemes following introduction

    Original URL path: http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/ (2015-10-30)
    Open archived version from archive

  • NCPE Natalizumab (Tysabri®) Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic Evaluation of Natalizumab Tysabri for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub optimally treated Pharmacoeconomic Evaluation Commenced Completed Outcome January 2007 April 2007 Reimbursement recommended Natalizumab could be considered borderline cost effective in the Irish healthcare setting In view of the uncertainty surrounding some of the ICERs a follow up

    Original URL path: http://www.ncpe.ie/drugs/natalizumab-tysabri/ (2015-10-30)
    Open archived version from archive

  • Rimonabant (Acomplia®) | National Centre for Pharmacoeconomics
    Research ICORN Education Rimonabant Acomplia In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive In June 2006 Sanofi Aventis submitted an evaluation of the cost effectiveness of rimonabant in addition to diet and exercise in the management of multiple cardiovascular risks in overweight or obese patients in Ireland to support its application for reimbursement of rimonabant under the Community Drugs Schemes The following report was

    Original URL path: http://www.ncpe.ie/drugs/rimonabant-acomplia-2/ (2015-10-30)
    Open archived version from archive

  • Drugs | National Centre for Pharmacoeconomics
    Research Pharmacoeconomic Research ICORN Education Drugs In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive A B C D E F G H I L M N O P R S T U V Radium 223 Xofigo Abatacept Orencia Abiraterone Acetate Zytiga for mCRPC Abiraterone acetate Zytiga for mCRPC post ADT Aclidinium bromide Eklira Genuair Aclidinium bromide formoterol fumarate dihydrate Brimica Genuair Adalimumab Humira Adenuric

    Original URL path: http://www.ncpe.ie/category/drugs/ (2015-10-30)
    Open archived version from archive